NCT02419560View on ClinicalTrials.gov

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Lymphoma, Mantle-CellRecurrent Lymphoma, Mantle-Cell
Interventions
DRUG

ABT-199 and Ibrutinib Combination

Both are administered orally once daily.

Trial Locations (4)

22908

University of Virginia, Charlottesville

30322

Winship Cancer Institute, Emory University, Atlanta

63110

Washington University School of Medicine, St Louis

91010

City of Hope, Duarte

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Craig Portell, MD

OTHER